Qdenga Dengue Vaccine Approval
The recent approval of the dengue vaccine Qdenga (TAK-003) by India’s Subject Expert Committee under the Drugs Controller General of India (DCGI) marks a significant advancement in combating dengue, a major public health concern. Developed by the Japanese pharmaceutical company Takeda, Qdenga is a tetravalent, live-attenuated vaccine designed to protect against all four dengue virus serotypes (DENV-1 to DENV-4).
Sign up free to read the full article
Access all current affairs, state notes, subject notes and more — completely free.